Tech Company Financing Transactions
YmAbs Therapeutics Funding Round
YmAbs Therapeutics, based in New York, secured $30 million from Scopia Capital Management and Sofinnova Ventures.
Transaction Overview
Company Name
Announced On
11/30/2017
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Proceeds Purpose
The proceeds of the financing will be used to advance the development of YmAbs portfolio of late-stage oncology compounds, establish sales and marketing capabilities, and bolster general working capital.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
230 Park Ave. 3350
New York, NY 10169
USA
New York, NY 10169
USA
Phone
Website
Email Address
Overview
YmAbs Therapeutics is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. Our lead antibody programs target GD2 and B7-H3. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Claus Moller
Chief Financial Officer
Bo Kruse
Chief Medical Officer
Steen Lisby
Chief Operating Officer
Joris Wilms
President
Thomas Gad
VP - Operations
Torben Lund-Hansen
Browse more venture capital transactions:
Prev: 11/29/2017: BetterLesson venture capital transaction
Next: 11/30/2017: Emu Technology venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs